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Abstract: Recurrent vulvovaginal candidiasis (RVVC) is predicted to increase to almost 158 million
cases annually by 2030. Extensive self-diagnosis and easily accessible over-the-counter (OTC)
fungistatic drugs contribute to antifungal-resistance, illustrating the need for novel therapies. Honey
possesses multiple antimicrobial mechanisms, and there is no antimicrobial resistance towards honey
reported. We evaluated the susceptibility of five clinical isolates of Candida albicans and a control strain
to regular honey and a medical grade honey (MGH) gel formulation (L-Mesitran, containing 40%
honey and vitamins C and E) using an adapted version of the EUCAST protocol at pH 5.2, 4.6, and 4.0.
40% regular honey did not kill or inhibit C. albicans. In contrast, the minimal inhibitory concentration
(MIC) of L-Mesitran was 25%–50%, while fungicidal effects occurred at a 50% concentration (MBC) of
the MGH formulation, except for one strain which was not killed at pH 4.0. Overall, pH had little
effect on antimicrobial activity. MGH formulation L-Mesitran has antimicrobial activity against C.
albicans over a relevant pH range. The vitamin supplements or other components of L-Mesitran
may enhance the antifungal activity of the honey. This study supports performing clinical trials for
conditions, such as RVVC, to find an alternative to available OTC fungistatic drugs.
Keywords: vaginitis; medical grade honey; candidiasis; candida; antibiotic resistance; recurrent
vulvovaginal candidiasis
1. Introduction
Candida albicans causes 80–92% of all vulvovaginal candidiasis (VVC) [1,2]. The number of
women worldwide suffering from recurrent VVC (RVVC) is expected to increase to almost 158 million
by 2030 [3]. Routine microscopy and culturing are considered the standard to diagnose vaginitis
in symptomatic women, but unfortunately these tests are often not done in practice, resulting in
inappropriate medication and persistence of symptoms [4]. Self-diagnosis was found to have an
accuracy rate of only 28% for C. albicans infection in self-treating women, and over-the-counter (OTC)
antifungal agents are often ineffective [5–7]. Although vaginal isolates of C. albicans are largely azole
sensitive currently, there is an increase in azole-resistance [8,9]. Possible causes of relapse include factors
such as host immune status and sensitivity to fungal antigen, in addition to errors in self-diagnosis and
self-medication. In this context, the availability of effective alternatives to azole antifungal agents with
different mechanisms of action could have a significant impact on the global burden of health-care
costs and patient’s lives.
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Honey is a natural substance that has been used for wound healing since ancient times [10].
The antibacterial and antifungal properties of honey can be ascribed to multiple mechanisms [11–18].
Honey contains over 200 different components, of which sugars, such as glucose and fructose,
encompasses the main part (70%) [19]. These sugars have a strong osmotic activity, which leads to
dehydration of the microorganisms. Glucose in contact with glucose oxidase releases small amounts
of hydrogen peroxide that can kill the already damaged pathogens. The low pH makes it hard
for pathogens to persist. In addition, honey contains several phytochemicals, including flavonoids
and alkaloids that have antioxidative and direct antimicrobial effects, such as propolis, pinocembrin,
chrysin, pinobanksin, galangin, quercetin, luteolin, and kaempferol [18,20,21]. Different honeys have
different flavonoid profiles and thus antimicrobial activity, depending on the floral source of the
nectar, geographic origin, environmental factors, and storage conditions [19]. Since the antimicrobial
mechanisms of honey act via multiple mechanisms, it is hard for pathogens to develop resistance
towards honey and this has not been described yet [22,23].
The MGH formulation investigated in this study (L-Mesitran) is indicated for fungating wounds.
However, we received feedback from women using L-Mesitran successfully off-label for the treatment
of vaginitis. To prevent off-label use and possibly expand its intended use for vaginitis in the future,
we here wanted to find in vitro evidence that L-Mesitran is able to kill C. albicans and to justify further
clinical studies. In this study, the susceptibility of C. albicans to honey and an MGH formulation
(L-Mesitran) was tested by evaluating five isolates from vaginal samples of symptomatic patients.
Tests were performed at a range of pH levels reflecting the natural acidic environment in the vagina.
In contrast to bacterial vaginosis, a low pH is maintained during Candida infections [24].
2. Materials and Methods
Candida isolates were obtained from the Southmead Hospital in Bristol, UK. To ensure that the
isolates were representative for the general population with common vaginal infections caused by
Candida, we randomly selected five clinical Candida albicans isolates from vaginal swab specimens
submitted for routine diagnostic purposes because of vaginal discharge. The isolates were confirmed
to be Candida albicans strains by mass spectrometry (Biotyper MALDI-TOF; Bruker UK, Coventry).
Samples were coded to prevent traceability back to the patient and guarantee anonymity. From two of
these isolates a resistance profile was made, showing these strains would be susceptible to common
antifungal agents, including azoles, amphotericin B, and caspofungin. We also included a control
strain (NCPF3179) in our experiments which is extensively characterized and used in antimicrobial
testing. These samples were not recruited as part of a specific study and patient consent was not
sought. The five isolates and the control were tested against unprocessed Mexican Yucatan honey
with hydrogen peroxide activity and L-Mesitran Soft (Triticum B.V., Maastricht, The Netherlands), a
formulation containing 40% of the same Mexican Yucatan honey, hypoallergenic lanolin (Medilan™,
Croda Inc.), propylene glycol, PEG4000, and vitamins C and E.
2.1. Preparation of Test Compounds and Microtiter Plates
Determination of the minimum inhibitory concentration (MIC) was performed based on the
‘EUCAST antifungal MIC method for yeasts’ but adapted to suit the nature and potency of the
compounds under evaluation [25]. Yeast-nitrogen base (YNB, with amino acids; Sigma Y1250) was
prepared at ×10 concentration according to manufacturer’s instructions and subsequently diluted to
double strength (ds) concentration with sterile water before pH was adjusted to 5.2, 4.6 or 4.0 (+/- 0.05)
with hydrochloric acid and filter sterilised. The rationale behind these pH values is that the vaginal pH
normally lays between pH 3.8 and 4.2, while an imbalance in the vaginal ecosystem is often considered
above pH 4.5, [26]. Honey products subjected to testing were provided by Theo Manufacturing B.V.,
Maastricht, The Netherlands (see Table 1).
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Table 1. Summary of tested compounds, their composition, and test conditions.
Test compound and
Composition Concentrations Tested
Equivalent Honey
Concentration Tested pH Levels
Raw honey used in
L-Mesitran 1 40%, 20%, 10%, 5% 40%, 20%, 10%, 5% 5.2, 4.6, 4.0
L-Mesitran soft wound
gel 2 50%, 25%, 12.5%, 6.25% 20%, 10%, 5%, 2.5% 5.2, 4.6, 4.0
1 100% pure honey; 2 40% medical grade honey (MGH).
Maximum concentrations of MGH formulation L-Mesitran and pure honey in test wells were
obtained by preparing emulsions in YNB rather than water according to:
x mL L-Mesitran + x mL ds YNB (resultant suspension equivalent to 20% honey), (1)
y mL honey + 0.25y mL H2O + 1.25y mL ds YNB
(resultant suspension equivalent to 40% honey),
(2)
where the resultant suspension was equivalent to 20% honey and 40% honey, respectively.
Each compound was suspended in ds YNB at pH 5.2, 4.6 and 4.0. To produce homogenous
suspensions, they were heated to 37 ◦C and mixed vigorously using a vortex mixer. The suspensions
were then serially diluted in two-fold steps in a 96-well plate (Corning®Costar®) using ×1 YNB of the
appropriate pH as the diluent. The final well containing ×1 YNB and no test compound served as
the control.
2.2. Inoculum Preparation
Candida albicans cells were collected and suspended in sterile water at a density equivalent to a
0.5 McFarland standard as per EUCAST instructions: colonies from 18–24-h cultures on Sabouraud’s
agar were suspended in 3 mL water and vortexed for 15 s. Turbidity was confirmed using a Vitek
Densichek (BioMerieux). Cell density was confirmed to be within the acceptable range (1.0–5.0 × 106
colony forming units per mL) by performing viable counts on Sabouraud’s agar.
To minimise any additional dilution of the product in the final assay, 10 µL of 0.5 McFarland
standard suspension was added to each 190 µL test well, rather than 100uL of a further 1/10 dilution
to 100 µL as mentioned in EUCAST recommendations, resulting in the specified 0.5–2.0 × 105 colony
forming units per mL final concentration in test wells. From each control well, 10 µL samples were
taken and plated onto Columbia Blood agar plates for purity checks and to serve as the pre-incubation
comparator for post incubation cultures (see below). The comparator plates were incubated at 37 ◦C
for 24 (+/-1) h.
2.3. Plate Reading
Following 24-h incubation at 37 ◦C, microtiter plates were removed and 10 µL samples were
taken from each test well, plated onto Columbia Blood agar and incubated at 37 ◦C for 24 h. Visual
examination normally specified for reading microdilution assays was not useful because the test
compounds rendered the wells turbid at the high concentrations tested. Hence, the minimum fungicidal
concentration (MFC) was defined as the minimum dilution of test compound resulting in no growth of
C. albicans in post-incubation subcultures (equivalent to a >103 kill). Likewise, the minimum inhibitory
concentration (MIC) was defined as the minimum dilution of a test compound that resulted in similar or
reduced growth of C. albicans in post-incubation subcultures when compared to pre-incubation controls.
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3. Results
The antifungal activities of both test compounds were consistent for all strains across the range
of pH levels tested. The MICs for L-Mesitran remained in the dilution range of 25 to 50%, which is
equivalent to a honey content of 10% and 20%, respectively. In almost all cases, the MFC for L-Mesitran
was 50%, equivalent to 20 honey content (see Figure 1). In contrast, when testing the pure honey
compound dilutions, no discernible inhibitory or cidal antimicrobial activity was noted at the highest
concentration of 40% (v/v) honey tested, giving MIC and MFC values >40% honey for all strains at all
pH levels tested.
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Figure 1. Activity of L-Mesitran against clinical Candida albicans isolates tested at pH 5.2, 4.6, and
4.0, shown as the minimum inhibitory concentrations (MIC) and minimum fungicidal concentrations
(MFC). NCPF 3179 was added as the control strain.
Minor strain-specific sensitivities to L-Mesitran were observed. An MIC of 50% L-Mesitran (20%
(v/v) honey content) was needed for isolate 5 at every pH, while the MIC for remaining isolates and/or
control strain typically was a 25% dilution of L-Mesitran (10% (v/v) honey content). Exceptions were
isolate 2, the control strain, and isolate 3 at pH 5.2, pH 4.6, and pH 4.0, respectively, which also needed
50% L-Mesitran to effectively inhibit the growth.
The MFC for Candida isolates 1 through 4, as well as the control strain, was 50% L-Mesitran in
every pH condition, which has a honey content of 20% (v/v). At pH 4.0, 50% L-Mesitran, containing
20% honey, was not cidal for isolate 5.
4. Discussion
Current research suggests that MGH might offer a valuable therapeutic alternative in the treatment
of VVC [14,15,18,27,28]. The results of this study showed no effect of 40% Mexican Yucatan MGH alone
against Candida albicans isolates, whereas the MGH product had fungistatic and fungicidal activity.
In vitro studies report relatively high minimal concentrations for the inhibition of Candida spp.; a study
on the antimicrobial capacities of Slovenian honeys reported no inhibition of different Candida spp. at
50% (v/v), a result si ilar to this study [29]. Other published MIC values for different kinds of honey
against C. albicans lie between 18% and 42% (v/v) or >60% (v/v) in some studies [14,15,27,28,30].
Interestingly, the supplements in the MGH formulation have enhanced the antimicrobial activity
of the honey formulation. Likely, this has been contributed by the antioxidants and vitamins C and E.
Numerous clinical studies have shown that vitamins C and E can have synergistic effects with antibiotics
and enhance the growth inhibition and the lethal effects of antibiotics against microorganisms [31–40].
Oliviera et al. investigated the antimicrobial activity of honey and L-Mesitran against S. pseudintermedius
isolates and M. pachydermatis fungi [41]. In line with our study, L-Mesitran demonstrated enhanced
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antimicrobial activity compared to honey, which were likely contributed by the other components in
the MGH formulation, such as the vitamins C and E [41]. Other supplements include lanolin and
PEG4000. Lanolin is applied to treat dry and irritated skin, as it aids in restoring the epidermal barrier
and reducing water loss of the skin [42]. Lanolin is sometimes said to be antimicrobial, but there is
limited scientific literature to substantiate this. As an emollient, it penetrates the skin into intracellular
spaces to form an emulsion with epidermal water which in turn can be released into the dry stratum
corneum layer where Candida spp. adhere and multiply in the infected vaginal tissue [43–46] . These
hydrating properties make it an excellent vehicle for retaining water-soluble antimicrobial agents,
such as MGH [40,46]. Poly-ethylene-glycols (PEGs) are a family of water-soluble linear polymers.
PEG4000 has a molecular weight of 4000 and is frequently used in a variety of pharmaceutical, cosmetic,
ophthalmic applications and enhances drug delivery [47]. No direct antimicrobial activity has been
described for PEG4000, however, it can improve the release of antimicrobial drugs [47].
The findings of this small-scale study offer insight into the fungicidal capacity of both pure honey
and an MGH-based compound at pH values 4.0 and 4.6 and 5.2, which are typically seen in VVC as well
as the healthy vagina [48]. The results of this study demonstrate some minor strain-specific antifungal
variation in MICs at different pH effects, but a concentration of minimally 50% (v/v) L-Mesitran was
demonstrated to have activity against all isolates, at all pH levels tested. Few of the reviewed studies
that have investigated pure honey’s ability to inhibit Candida spp. investigated the effect of pH [49].
The contribution of honey in alleviating vaginal discomfort caused by Candida infections has been
demonstrated in various in vivo studies where by day 8 fewer individuals suffered from symptoms
including inflammation, vaginal discharge, itching, and dyspareunia in the honey group as compared
to azole control groups [27,49,50]. The ointments evaluated in these studies consisted of either pure
unprocessed honey or homogenous ointments with honey contents of 50–70% (v/v). The effect an
MGH formulation would have when being delivered to the site of infection remains to be elucidated.
Therefore, future research should investigate whether the deposition of an MGH formulation enriched
by antioxidant supplements could convey anti-inflammatory and immunostimulatory properties on
site to effectively control vaginal Candida infections. The gel evaluated in this study has been the subject
of a small Dutch anecdotal clinical study. In their study, Boon (2002) evaluated immune cell infiltration,
bacterial and yeast growth and vaginal complaints in thirty symptomatic women following the vaginal
application of L-Mesitran [51]. Overall reactions of the women were positive and microscopy of the
vaginal flora before and after the seven-day treatment period with the MGH ointment showed rapid
eradication of yeast cells and reduction of inflammation. MGH forms a promising alternative to
antifungal drugs without the risk of developing resistance. Since these findings imply the feasibility of
the clinical vaginal application of MGH, future research should be conducted on the clinical application
of MGH formulations whilst evaluating the treatment time, patient experience, and comfort.
5. Conclusions
In conclusion, in vitro research should not disregard the potential effect of environmental pH on
antimicrobial susceptibility of vaginal pathogens. The MGH formulation L-Mesitran has antifungal
activity against clinical Candida albicans isolates at minimum 50% v/v dilution (a honey content of at
least 20% v/v). The vitamins supplemented to L-Mesitran may enhanced the antimicrobial activity,
since a concentration of 40% honey did not show antifungal activity. This data supports the further
investigation of L-Mesitran in clinical studies as an alternative to available OTC fungistatic drugs in
conditions such as VVC.
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